Jill Wilcox Hall Email & Phone Number

Atlanta, Georgia

Greater Atlanta Area, Ga

Account Manager for Janssen CNS- Mental Health Division. Primary focus is on promoting long acting injectable therapy – Atypical Antipsychotic, Invega Sustenna & Invega Trinza, for the schizophrenia & schizoaffective market. Calling on area community mental health systems, including outpatient CSBs, ACT teams and private practice psychiatrists.• Current overall rank #7 Invega Sustenna & # 4 Invega Trinza in the nation, 2018• Conducted #7 speaker programs to date, 2018• Market Volume change rank #4 for Invega Sustenna & Invega Trinza, YTD, 2017 • Finshed Q4 ranked #1 in the South Region for Invega Sustenna & Invega Trinza, 2017

Atlanta West, Ga; Chattanooga, Athens & Cleveland Tn

Re-Launched Fanapt, Atypical Antipsychotic for adult patients with schizophrenia. Targets included private practice psychiatrists, community mental health centers and specialty pharmacies.

Atlanta, Augusta, North Ga

Account Manager for Janssen CNS team. Called on outpatient CSBs and private practice psychiatrists. Responsible for new market penetration with injectable antipsychotic, Invega Sustenna (IS) & Invega Trinza (IT) for patients with schizophrenia. In-service focus with the entire treatment team, including psychiatrists, nurses, counselors, therapists and pharmacists. • Market volume growth 105 % for (IS & IT) YTD, 2016• Exceeded Expectations (EE) for performance review, 2015• Grew Invega Sustenna market share 30%, 2014• Coordinated with Janssen’s ‘System of Care’ representative to facilitate patient access with injection sites• Developed Care Transition Plans for hospitalized patients transitioning to community service boards

Greater Atlanta Area

Re-launched Urinary Tract Antiseptic, UTA with urologists and OBGYNs. Educated physicians on protecting the Rx as brand necessary. Increased sales for 14 cough and cold prescription medications with target PCPs. Launched PolyHist PD drops, Antihistamine/ Antitussive.~ Achieved #1 leader position with highest UTA sales, closing out 4th quarter, 2013

Greater Atlanta Area

Launched new insomnia therapy, Intermezzo, through the Purdue Pharma contract. Educated specific targeted primary care physicians, sleep specialists and pharmacies. Increased prescription growth and market share in assigned territory. Achieved weekly, quarertly and annual goals.

Greater Atlanta Area

Increased sales of Depakote®/Depakote ER®/Depacon IV within a multitude of key accounts to include hospitals, mental health clinics, teaching institutions as well as private practice Neurologists and Psychiatrists. ~Finished top 30% of All-Star rankings, 2008-20011Maintained market share of branded Depakote®/Depakote ER® while the nation’s overall market decreased in a generic environment. Promoted Synthroid® to a select group of target physicians in Endocrinology, Internal Medicine, OBGYN and Primary Care. Member of Regional Manager's Leadership Team.Developed two key Epileptologists as opinion leaders and regional speakers. Successfully launched 3 new indications with Depakote®/Depakote ER®/Depacon IV. Gained formulary access for promoted products.Appointed Regional Field Trainer for Pain Care sales team expansion.Created pharmacy call achievement cycle to accelerate conversion of CoPay card program.

Greater Chicago Area

Managed military, government, staff model and HMO key accounts. Gained formulary approval for new pharmaceutical products, and implemented value added programs with hospital administration.

Greater Milwaukee Area

Interfaced with Primary Care Pharmacutical Sales representatives. Increased market share with Gastroenterologists, Otolaryngologists, Allergists and Pulmonologists key accounts.

Schaumburg, Il

Launched and grew sales dollars / volume of promoted products, Biaxin, Hytrin, Ogen and Prosom to Primary Care and Internal Medicine physicians.

Bba, Marketing

Activities and Societies: Alpha Sigma Alpha

Associate Science, General Studies